Ascenta Capital
Finance · United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.ascentacap.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
2
1
1
1
About Ascenta Capital
Ascenta Capital is dedicated to helping innovative biotech companies transition from scientific foundations to the clinical development of impactful medicines for patients. With $335 million in assets under management, they focus on concentrated investments ranging from $15 to $30 million, providing strategic and operational support to management teams. Their patient-centered approach ensures that investments are made in innovations that significantly improve patient lives. Ascenta Capital partners with companies in early development phases, leveraging deep scientific insights and resources to foster sustainable growth.Explore more
Ascenta Capital Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ascenta Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ascenta Capital had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Ascenta Capital has new funding data
Earning: See what the market has to say on Ascenta Capital recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Ascenta Capital
Check if Ascenta Capital has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Ascenta Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Ascenta Capital is spiking on competitors!
Product Launch: Get notified when Ascenta Capital launches new products
Recommended Actions
Find VP level buyers at Ascenta Capital
Find 3 more new buyers
Compare Similar Companies to Ascenta Capital
Compare insights from companies similar to Ascenta Capital, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ascenta Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Ascenta Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Ascenta Capital.
Ascenta Capital Tech Stack
A closer look at the technologies used by Ascenta Capital
See more technologies
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Ascenta Capital News & Media
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to ...
Series C led by Lightspeed Venture Partners and Ascenta Capital with participation from top-tier new investor syndicate and existing investorsFunding will advance distinctive pipeline of targeted radiopharmaceuticals through clinical studiesCardurion Pharmaceuticals Raises $260M Series B Financing
Cardurion Pharmaceuticals, Inc., a Burlington, MA-based clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, raised $260m in Series B financing. The round was led by Ascenta Capital, with participation by new investors NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital […] The post Cardurion Pharmaceuticals Raises $260M SeOdyssey Therapeutics Announces $101 Million Series C Financing
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the closing of a $101 million Series C financing round led by Ascenta Capital with participation from new and existing investors, including OrbiMed, SR One, General Catalyst, Foresite Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures, BlackMars Capital GmbH, Creacion Ventures, funds and accounts advised
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ascenta Capital
Sign Up For FreeTo access detailed company insights
Ascenta Capital is dedicated to helping innovative biotech companies transition from scientific foundations to the clinical development of impactful medicines for patients. With $335 million in assets under management, they focus on concentrated investments ranging from $15 to $30 million, providing strategic and operational support to management t... Read More
